Agios to Present at Upcoming Investor Conferences

Core Insights - Agios Pharmaceuticals is a leader in cellular metabolism and PK activation, focusing on therapies for rare diseases [1][2] - The company has scheduled presentations at multiple conferences in March 2025, which will be accessible via live webcasts [1][3] Company Overview - Agios is dedicated to developing transformative therapies for patients with rare diseases, including a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency [2] - The company has a robust clinical pipeline targeting conditions such as alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, myelodysplastic syndromes (MDS)-associated anemia, and phenylketonuria (PKU) [2] - Agios is also advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera [2] Upcoming Events - The company will participate in the Leerink Global Healthcare Conference 2025 on March 11, 2025, at 10:50 a.m. ET [3] - Agios will also be featured at the Barclays 27th Annual Global Healthcare Conference on March 12, 2025, at 12:30 p.m. ET [3]